Results 211 to 220 of about 71,715 (302)

Cardiac resident macrophages: the emerging role in arrhythmogenesis. [PDF]

open access: yesFront Immunol
Zhao J   +6 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang   +7 more
wiley   +1 more source

Prostatic Escherichia coli infection drives CCR2-dependent recruitment of fibrocytes and collagen production

open access: yesDisease Models & Mechanisms
Brandon R. Scharpf   +10 more
doaj   +1 more source

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao   +5 more
wiley   +1 more source

Truncated FOS impairs osteogenic differentiation and induces prostaglandin and NFκB signalling in an in vitro cell‐of‐origin model for osteoid osteoma and osteoblastoma

open access: yesThe Journal of Pathology, Volume 268, Issue 3, Page 263-275, March 2026.
Abstract Osteoid osteoma and osteoblastoma are non‐malignant bone‐forming tumours of the skeleton, characterised by the presence of irregular trabeculae of woven bone. Rearrangements in FOS, and less frequently FOSB, have recently been identified in osteoid osteoma and osteoblastoma.
Suk Wai Lam   +10 more
wiley   +1 more source

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

open access: yesThe Lancet Oncology, 2016
T. Nywening   +20 more
semanticscholar   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

open access: yesWIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

Home - About - Disclaimer - Privacy